Length Polymorphisms in Human Proline-Rich Protein Genes Generatedby Intragenic Unequal Crossing Over
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cow's Milk Allergy in Dutch Children
Petrus et al. Clin Transl Allergy (2016) 6:16 DOI 10.1186/s13601-016-0105-z Clinical and Translational Allergy RESEARCH Open Access Cow’s milk allergy in Dutch children: an epigenetic pilot survey Nicole C. M. Petrus1*†, Peter Henneman2†, Andrea Venema2, Adri Mul2, Femke van Sinderen2, Martin Haagmans2, Olaf Mook2, Raoul C. Hennekam1,2, Aline B. Sprikkelman1‡ and Marcel Mannens2‡ Abstract Background: Cow’s milk allergy (CMA) is a common disease in infancy. Early environmental factors are likely to con- tribute to CMA. It is known that epigenetic gene regulation can be altered by environmental factors. We have set up a proof of concept study, aiming to detect epigenetic associations specific with CMA. Methods: We studied children from the Dutch EuroPrevall birth cohort study (N 20 CMA, N 23 controls, N 10 tolerant boys), age and gender matched. CMA was challenge proven. Bisulfite converted= DNA =(blood) was analyzed= using the 450K infinium DNA-methylation array. Four groups (combined, girls, boys and tolerant boys) were analysed between CMA and controls. Statistical analysis and pathway-analysis were performed in “R” using IMA, Minfi and the global-test package. Differentially methylated regions in DHX58, ZNF281, EIF42A and HTRA2 genes were validated by quantitative amplicon sequencing (ROCHE 454®). Results: General hypermethylation was found in the CMA group compared to control children, while this effect was absent in the tolerant group. Methylation differences were, among others, found in regions of DHX58, ZNF281, EIF42A and HTRA2 genes. Several of these genes are known to be involved in immunological pathways and associated with other allergies. Conclusion: We show that epigenetic associations are involved in CMA. -
Identification of ROBO2 As a Potential Locus Associated with Inhaled
Journal of Personalized Medicine Article Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma Natalia Hernandez-Pacheco 1,2,3,*,†, Mario Gorenjak 4 , Jiang Li 5 , Katja Repnik 4,6, Susanne J. Vijverberg 7,8,9, Vojko Berce 4,10 , Andrea Jorgensen 11, Leila Karimi 12 , Maximilian Schieck 13,14, Lesly-Anne Samedy-Bates 15,16, Roger Tavendale 17, Jesús Villar 3,18,19 , Somnath Mukhopadhyay 17,20, Munir Pirmohamed 21 , Katia M. C. Verhamme 12, Michael Kabesch 13, Daniel B. Hawcutt 22,23, Steve Turner 24 , Colin N. Palmer 17, Kelan G. Tantisira 5,25, Esteban G. Burchard 15,16, Anke H. Maitland-van der Zee 7,8,9 , Carlos Flores 1,3,26,27 , Uroš Potoˇcnik 4,6,*,‡ and Maria Pino-Yanes 2,3,27,‡ 1 Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Carretera General del Rosario 145, 38010 Santa Cruz de Tenerife, Spain; cfl[email protected] 2 Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, Avenida Astrofísico Francisco Sánchez s/n, Faculty of Science, Apartado 456, 38200 San Cristóbal de La Laguna, Spain; [email protected] 3 CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Avenida de Monforte de Lemos, 5, 28029 Madrid, Spain; [email protected] 4 Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia; [email protected] (M.G.); [email protected] (K.R.); [email protected] -
Supplementary Data
Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type -
Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva
UCSF UC San Francisco Previously Published Works Title Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva. Permalink https://escholarship.org/uc/item/95h5g8mq Journal Cell reports, 33(7) ISSN 2211-1247 Authors Saitou, Marie Gaylord, Eliza A Xu, Erica et al. Publication Date 2020-11-01 DOI 10.1016/j.celrep.2020.108402 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cell Rep Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 November 30. Published in final edited form as: Cell Rep. 2020 November 17; 33(7): 108402. doi:10.1016/j.celrep.2020.108402. Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva Marie Saitou1,2,3, Eliza A. Gaylord4, Erica Xu1,7, Alison J. May4, Lubov Neznanova5, Sara Nathan4, Anissa Grawe4, Jolie Chang6, William Ryan6, Stefan Ruhl5,*, Sarah M. Knox4,*, Omer Gokcumen1,8,* 1Department of Biological Sciences, University at Buffalo, The State University of New York, Buffalo, NY, U.S.A 2Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, U.S.A 3Faculty of Biosciences, Norwegian University of Life Sciences, Ås, Viken, Norway 4Program in Craniofacial Biology, Department of Cell and Tissue Biology, School of Dentistry, University of California, San Francisco, CA, U.S.A 5Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY, U.S.A 6Department of Otolaryngology, School of Medicine, University of California, San Francisco, CA, U.S.A 7Present address: Weill-Cornell Medical College, Physiology and Biophysics Department 8Lead Contact SUMMARY Salivary proteins are essential for maintaining health in the oral cavity and proximal digestive tract, and they serve as potential diagnostic markers for monitoring human health and disease. -
The Genome-Wide Landscape of Copy Number Variations in the MUSGEN Study Provides Evidence for a Founder Effect in the Isolated Finnish Population
European Journal of Human Genetics (2013) 21, 1411–1416 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg ARTICLE The genome-wide landscape of copy number variations in the MUSGEN study provides evidence for a founder effect in the isolated Finnish population Chakravarthi Kanduri1, Liisa Ukkola-Vuoti1, Jaana Oikkonen1, Gemma Buck2, Christine Blancher2, Pirre Raijas3, Kai Karma4, Harri La¨hdesma¨ki5 and Irma Ja¨rvela¨*,1 Here we characterized the genome-wide architecture of copy number variations (CNVs) in 286 healthy, unrelated Finnish individuals belonging to the MUSGEN study, where molecular background underlying musical aptitude and related traits are studied. By using Illumina HumanOmniExpress-12v.1.0 beadchip, we identified 5493 CNVs that were spread across 467 different cytogenetic regions, spanning a total size of 287.83 Mb (B9.6% of the human genome). Merging the overlapping CNVs across samples resulted in 999 discrete copy number variable regions (CNVRs), of which B6.9% were putatively novel. The average number of CNVs per person was 20, whereas the average size of CNV per locus was 52.39 kb. Large CNVs (41 Mb) were present in 4% of the samples. The proportion of homozygous deletions in this data set (B12.4%) seemed to be higher when compared with three other populations. Interestingly, several CNVRs were significantly enriched in this sample set, whereas several others were totally depleted. For example, a CNVR at chr2p22.1 intersecting GALM was more common in this population (P ¼ 3.3706 Â 10 À44) than in African and other European populations. The enriched CNVRs, however, showed no significant association with music-related phenotypes. -
1 Proteins of the XMRV Retrovirus Implicated in Chronic Fatigue
1 Proteins of the XMRV retrovirus implicated in chronic fatigue syndrome and prostate cancer are homologous to human proteins relevant to both conditions. C.J.Carter Flat 4, 20 Upper Maze Hill, Saint-Leonards on Sea , East Sussex, TN38 OLG [email protected] The XMRV retrovirus has been implicated in chronic fatigue syndrome and prostate cancer. A homology search comparing retroviral with human proteins revealed short contiguous amino acid strings (typically 5-8 aa) matching human proteins whose dysfunction might be expected to cause fatigue, including mitochondrial proteins related to oxidative phosphorylation, glutamate receptors and their synaptic scaffolds, muscular acetylcholine receptor scaffolds and structural proteins, components of the immune system, and phosphatidylinositol signalling inter alia. Viral proteins are also homologous to members of the oestrogen, peroxisome proliferator, and CREB activated receptor networks, all of which are implicated in prostate cancer, and to a protein, SRCAP, that controls the expression of the prostate- specific antigen. These short matches are often predicted to be antigenic, and antibodies to XMRV proteins may target their human homologues. This is supported by the presence of autoantibodies to muscarinic receptors , vimentin and LAMINB1 (all XMRV homologues) in chronic fatigue syndrome sufferers. Homologous XMRV proteins might also interfere with the protein interactomes of their human homologues. Viral mimicry of human proteins is extensive and often relevant to disease. For example Epstein-Barr viral proteins aligns with multiple sclerosis autoantigens, while HIV-1 proteins align with several components of the immune system. Mutant proteins in Huntington’s disease and cystic fibrosis also align with proteins from common phages or viruses. -
Genome-Wide Postnatal Changes in Immunity Following Fetal Inflammatory Response
medRxiv preprint doi: https://doi.org/10.1101/19000109; this version posted September 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Genome-wide postnatal changes in immunity following fetal inflammatory response Daniel Costa1,2, Núria Bonet3, Amanda Solé2,4,5, José Manuel González de Aledo-Castillo6, Eduard Sabidó2,4,5, Ferran Casals3, Carlota Rovira7, Alfons Nadal8, Jose Luis Marin9, Teresa Cobo9,*, Robert Castelo2,10,* 1Department of Pediatrics, Hospital de Figueres, Figueres, Spain; 2Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain; 3Genomics Core Facility, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain; 4Proteomics Unit, Centre de Regulació Genòmica (CRG), Barcelona, Spain; 5Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; 6Inborn Errors of Metabolism Section, Laboratory of Biochemistry and Molecular Genetics, Hospital Clínic, Barcelona, Spain; 7Hospital Sant Joan de Déu, Barcelona, Spain; 8Department of Pathology, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 9Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain; 10Research Programme on Biomedical Informatics, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain; *Correspondence: Robert Castelo ([email protected]), Teresa Cobo ([email protected]) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
(12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub
US 2003O19897OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub. Date: Oct. 23, 2003 (54) GENOSTICS clinical trials on groups or cohorts of patients. This group data is used to derive a Standardised method of treatment (75) Inventor: Gareth Wyn Roberts, Cambs (GB) which is Subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying Correspondence Address: the individual variability in response to disease, therapy and FINNEGAN, HENDERSON, FARABOW, prognosis lies in a person's genetic make-up. There have GARRETT & DUNNER been numerous examples relating that polymorphisms LLP within a given gene can alter the functionality of the protein 1300 ISTREET, NW encoded by that gene thus leading to a variable physiological WASHINGTON, DC 20005 (US) response. In order to bring about the integration of genomics into medical practice and enable design and building of a (73) Assignee: GENOSTIC PHARMA LIMITED technology platform which will enable the everyday practice (21) Appl. No.: 10/206,568 of molecular medicine a way must be invented for the DNA Sequence data to be aligned with the identification of genes (22) Filed: Jul. 29, 2002 central to the induction, development, progression and out come of disease or physiological States of interest. Accord Related U.S. Application Data ing to the invention, the number of genes and their configu rations (mutations and polymorphisms) needed to be (63) Continuation of application No. 09/325,123, filed on identified in order to provide critical clinical information Jun. 3, 1999, now abandoned. concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. -
PRB4 Conjugated Antibody
Product Datasheet PRB4 Conjugated Antibody Catalog No: #C29940 Package Size: #C29940-AF350 100ul #C29940-AF405 100ul #C29940-AF488 100ul Orders: [email protected] Support: [email protected] #C29940-AF555 100ul #C29940-AF594 100ul #C29940-AF647 100ul #C29940-AF680 100ul #C29940-AF750 100ul #C29940-Biotin 100ul Description Product Name PRB4 Conjugated Antibody Host Species Rabbit Clonality Polyclonal Isotype IgG Purification Affinity purification Applications most applications Species Reactivity Ms,Rt Immunogen Description Recombinant fusion protein of human PRB4 (NP_002714.2). Conjugates Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750 Other Names PRB4; Po; basic salivary proline-rich protein 4 Accession No. Swiss-Prot#:P10163NCBI Gene ID:5545 Calculated MW 31kDa Formulation 0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide Storage Store at 4°C in dark for 6 months Application Details Suggested Dilution: AF350 conjugated: most applications: 1: 50 - 1: 250 AF405 conjugated: most applications: 1: 50 - 1: 250 AF488 conjugated: most applications: 1: 50 - 1: 250 AF555 conjugated: most applications: 1: 50 - 1: 250 AF594 conjugated: most applications: 1: 50 - 1: 250 AF647 conjugated: most applications: 1: 50 - 1: 250 AF680 conjugated: most applications: 1: 50 - 1: 250 AF750 conjugated: most applications: 1: 50 - 1: 250 Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000 Background This gene encodes a member of the heterogeneous family of basic, proline-rich, human salivary glycoproteins. The encoded preproprotein undergoes proteolytic processing to generate one or more mature peptides before secretion from the parotid glands. Multiple alleles of this gene exhibiting variations in the length of the tandem repeats have been identified. -
PRB4 Rabbit Pab
Leader in Biomolecular Solutions for Life Science PRB4 Rabbit pAb Catalog No.: A16701 Basic Information Background Catalog No. This gene encodes a member of the heterogeneous family of basic, proline-rich, human A16701 salivary glycoproteins. The encoded preproprotein undergoes proteolytic processing to generate one or more mature peptides before secretion from the parotid glands. Observed MW Multiple alleles of this gene exhibiting variations in the length of the tandem repeats 31kDa have been identified. The reference genome encodes the "Small" allele. This gene is located in a cluster of closely related salivary proline-rich proteins on chromosome 12. Calculated MW Alternative splicing results in multiple transcript variants encoding different isoforms 31kDa that may undergo similar proteolytic processing. Category Primary antibody Applications WB Cross-Reactivity Human, Mouse Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 5545 P10163 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 178-247 of human PRB4 (NP_002714.2). Synonyms PRB4;Po Contact Product Information 400-999-6126 Source Isotype Purification Rabbit IgG Affinity purification [email protected] www.abclonal.com.cn Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using PRB4 antibody (A16701) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 3min. Antibody | Protein | ELISA Kits | Enzyme | NGS | Service For research use only. -
Bioactive Peptides Hidden in Human Salivary Proteins
Journal of Oral Biosciences 59 (2017) 71–79 Contents lists available at ScienceDirect Journal of Oral Biosciences journal homepage: www.elsevier.com/locate/job Review Bioactive peptides hidden in human salivary proteins Eiichi Saitoh a,n, Masayuki Taniguchi b, Akihito Ochiai b, Tetsuo Kato c, Akane Imai d, Satoko Isemura d a Graduate School of Technology, Niigata Institute of Technology, 1719 Fujihashi, Kashiwazaki, Niigata 945-1195, Japan b Department of Materials Science and Technology, Graduate School of Science and Technology, Niigata University, Niigata 950-2181, Japan c Laboratory of Chemistry, Tokyo Dental College, Tokyo 101-0062, Japan d Department of Dental Hygiene, The Nippon Dental University College at Niigata, Niigata 951-8580, Japan article info abstract Article history: Background: Extensive peptidomic studies of human saliva have resulted in considerable advances in the field Received 28 September 2016 of proteomics. As the next generation in salivary research, a comprehensive understanding of the biological Received in revised form functions of in vivo peptides generated by proteolysis in the oral cavity has been long awaited. A cyclopedic 4 November 2016 functional analysis of salivary peptides may bring promising therapeutic agents and novel clinical applications. Accepted 17 November 2016 Highlight: (1) This review article refers to bioactive peptides hidden in salivary parent proteins. (2) Functions of Available online 5 December 2016 the peptides as anti-microbial, anti-viral, wound-closing, and anti-pain are described. (3) Biological sig- Keywords: nificances of the repeated structures in salivary proline-rich proteins are emphasized. Human salivary proteome Conclusion: Human salivary proteins have the ability to generate bioactive peptides upon proteolytic cleavage. -
12P Deletion Spectrum Syndrome: a New Case Report Reinforces The
Leyser et al. Molecular Cytogenetics (2016) 9:75 DOI 10.1186/s13039-016-0278-0 CASE REPORT Open Access 12p deletion spectrum syndrome: a new case report reinforces the evidence regarding the potential relationship to autism spectrum disorder and related developmental impairments Marcio Leyser1*, Bruno Leonardo Dias1, Ana Luiza Coelho1, Marcio Vasconcelos2 and Osvaldo J. M. Nascimento2 Abstract Background: Autism Spectrum Disorders (ASD) now encompass a broad heterogeneous group of people who present in the early developmental years with a wide range of social and communication deficits, which are typically also associated with complex repetitive behaviors and circumscribed interests. The target goal is to heighten readers’ perception into the trend to personalize the distinct autistic and related developmental conditions encompassing the 12p region. Case Presentation: This is a case-report of a 4-year-old male who presented the core signs of ASD, which were thought to be related to a rare 12p13.2 deletion. We further reviewed the literature in order to outline the related developmental conditions in the 12p region. Aside from this patient reported here, we found an additional number of 43 cases described in the medical literature since 1974, that have been related to deletions in the 12p region. However, to the best of our knowledge, none of the previous had been specifically linked to the 12p13.2 band. Conclusions: The 12p deletion spectrum is rarely described as part of the selective genotypes thought to be related to ASD. Even inside of a small piece of the puzzle, there might be ample variation in the behavioral and clinical phenotypes of children and adults presenting with this particular genetic profile.